Zombie Shark

Lauren and JJ investigate a case of collapse in a middle-aged dog.
This episode includes a detailed discussion of hemoabdomen and
splenic hemangiosarcoma in the dog. References Primary sources of
information for this episode: (1) Rothrock, K., Smrkovski, K.,
& Rosenthal, R. C. (2021). Hemangiosarcoma, splenic (canine).
VINcyclopedia. Last updated 5/8/2021. Last accessed 5/26/2022.
www.vin.com (2) Pope, K. (2018). Evidince-informed integrative
oncology: Canine splenic hemangiosarcoma. Southwest Veterinary
Symposium Proceedings, 2018. Information about rates of metastasis,
splenectomy as a palliative procedure, and poor overall survival
rates: (1) Pope, K. (2018). Evidince-informed integrative oncology:
Canine splenic hemangiosarcoma. Southwest Veterinary Symposium
Proceedings, 2018. (2) Clifford, C. A. & Liptak, J. M. (2017).
Splenic tumors. Atlantic Coast Veterinary Conference Proceedings,
2017. (3) Batschinski, K., Nobre, A., Vargas-Mendez, E., Tedardi,
M. V., Cirillo, J., Castari, G., Ubukata, R., & Dagli, M. L.
(2018). Canine visceral hemangiosarcoma treated with surgery alone
or surgery and doxorubicin: 37 cases (2005-2014). The Canadian
Veterinary Journal, 59(9), 967-972. (4) Wendelburg, K. M., Price,
L. L., Burgess, K. E., Lyons, J. A., Lew, F. H., & Berg, J.
(2015). Survival time of dogs with splenic hemangiosarcoma treated
by splenectomy with or without adjuvant chemotherapy: 208 cases
(2001-2012). Journal of the American Veterinary Medical
Association, 247(4), 393-403. Information about median survival
times: (1) Thamm, D., Withrow, S. W. (2013). Miscellaneous tumors:
Hemangiosarcoma. Withrow & MacEwen’s Small Animal Clinical
Oncology,St. Louis, MO. Saunders/Elsevier, 679-88. (2) Aronsohn, M.
G., Dubiel, B., Roberts, B., & Powers, B. E. (2009). Prognosis
for acute nontraumatic hemoperitoneum in the dog: a retrospective
analysis of 60 cases (2003-2006). Journal of the American Animal
Hospital Association, 45(2), 72–77. (3) Collard, F., Nadeau, M. E.,
& Carmel, E. N. (2010). Laparoscopic splenectomy for treatment
of splenic hemangiosarcoma in a dog. Veterinary surgery : VS,
39(7), 870–872. (4) Marconato, L., Chalfon, C., Finotello, R.,
Polton, G., Vasconi, M. E., Annoni, M., Stefanello, D., Mesto, P.,
Capitani, O., Agnoli, C., Amati, M., & Sabattini, S. (2019).
Adjuvant anthracycline-based vs metronomic chemotherapy vs no
medical treatment for dogs with metastatic splenic hemangiosarcoma:
A multi-institutional retrospective study of the Italian Society of
Veterinary Oncology. Veterinary and comparative oncology, 17(4),
537–544. A selection of information about chemotherapy and
adjunctive treatments for hemangiosarcoma (outside of the scope of
this episode, for further reading): (1) Wendelburg, K. M., Price,
L. L., Burgess, K. E., Lyons, J. A., Lew, F. H., & Berg, J.
(2015). Survival time of dogs with splenic hemangiosarcoma treated
by splenectomy with or without adjuvant chemotherapy: 208 cases
(2001-2012). Journal of the American Veterinary Medical
Association, 247(4), 393-403. (2) Alexander, C. K., Cronin, K. L.,
Silver, M., Gardner, H. L., & London, C. (2019). The addition
of metronomic chemotherapy does not improve outcome for canine
splenic haemangiosarcoma. Journal of Small Animal Practice, 66(1),
32-37. (3) Matsuyama, A., Poirier, V. J., Mantovani, F., Foster, R.
A., & Mutsaers, A. J. (2017). Adjuvant doxorubicin with or
without metronomic cyclophosphamide for canine splenic
hemangiosarcoma. Journal of the American Animal Hospital
Association, 53(6), 304-312. (4) Teske, E., Rutteman, G. R.,
Kirpenstein, J., & Hirschberger, J. (2011). A randomized
controlled study into the efficacy and toxicity of pegylated
liposome encapsulated doxorubicin as an adjuvant therapy in dogs
with splenic haemangiosarcoma. Veterinary and Comparative Oncology,
9(4), 283-89. (5) Kahn, S. A., Mullin, C. M., de Lormier, L. P.,
Burgess, K. E., Risbon, R. E., Fred, R. M., Drobatz, K., &
Clifford, C. A. (2013) Doxorubicin and deracoxib adjuvant therapy
for canine splenic hemangiosarcoma: A pilot study. The Canadian
Veterinary Journal, 54(3) 237-42. (6) Kim, S. E., Liptak, L. M.,
Gall, T. T., Montelth, G. J., & Woods, P. (2007). Epirubicin in
the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases
(1997-2004). Journal of the American Veterinary Medical
Association, 231(10), 1550-57. (7) Alvarez, F. J., Hosoya, K.,
Lara-Garcia, A., Kisseberth, W., & Couto, G. (2013). VAC
protocol for treatment of dogs with stage III hemangiosarcoma.
Journal of the American Animal Hospital Association, 49(6), 370-77.
(8) Marconato, L., Chalfon, C., Finotello, R., Polton, G., Vasconi,
M. E., Annoni, M., Stefanello, D., Mesto, P., Capitani, O., Agnoli,
C., Amati, M., & Sabattini, S. (2019). Adjuvant
anthracycline-based vs metronomic chemotherapy vs no medical
treatment for dogs with metastatic splenic hemangiosarcoma: A
multi-institutional retrospective study of the Italian Society of
Veterinary Oncology. Veterinary and Comparative Oncology, 17(4),
537-44. (9) Gardner, H. L., London, C. A., Portela, R. A., Nguyen,
S., Rosenberg, M. P., Klein, M. K., Clifford, C., Thamm, D. H.,
Vail, D. M., Bergman, P., Crawford-Jakubiak, M., Henry, C., Locke,
J., & Garrett, L. D. (2015). Maintenance therapy with toceranib
following doxorubicin-based chemotherapy for canine splenic
hemangiosarcoma. BioMed Central Veterinary Research, 11(0), 131.
(10) Lana, S., U'ren, L., Plaza, S., Elmslie, R., Gustafson, D.,
Morley, P., & Dow, S. (2007). Continuous low-dose oral
chemotherapy for adjuvant therapy of splenic hemangiosarcoma in
dogs. Journal of Veterinary Internal Medicine, 21(4), 764-69. (11)
Vail, D. M., MacEwen, E. G., Kurzman, I. D., Dubielzig, R. R.,
Helfand, S. C., Kisseberth, W. C., London, C. A., Obradovich, J.
E., Madewell, B. R., & Rodriguez, C. O. (1995).
Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine
adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a
randomized multi-institutional clinical trial. Clinical Cancer
Research: An Official Journal of the American Association for
Cancer Research, 1(10), 1165-70. (12) Grammel, T. (2016). A pilot,
uncontrolled study of postsurgical treatment with autologous
dendritic cell-based immunologic therapy in 10 dogs with splenic
hemangiosarcoma. Veterinary Cancer Society World Congress
Proceedings, 2016.